Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe


Recursion Pharmaceuticals (NASDAQ: RXRX) and 23andMe (NASDAQ: ME) are both popular biotech stocks that are wooing investors with their claims about using artificial intelligence (AI) to supercharge the drug development process. But over the last three years, share prices of Recursion have lost 72% of their value, whereas 23andMe's stock is down 89%.

Given the expanding interest in anything related to AI, however, there's a good chance that the next three years could be better for both of these companies and their stocks.

Let's examine their prospects and determine which of these two biotech stocks is the better investment. 

Continue reading


Source Fool.com

Like: 0
Share

Comments